目的:探讨奈达铂化疗联合同期放疗治疗中晚期宫颈癌临床疗效,总结治疗经验。方法:选取中晚期宫颈癌患者40例,随机分为对照组与观察组各20例,对照组给予单纯的放射治疗,观察组给予以奈达铂为基础的同步放化疗。疗程结束后对比疗效与不良反应。结果:观察组总有效率90.00%、不良反应主要是消化道反应和骨髓抑制共15例次。对照组总有效率60.00%、不良反应主要是消化道反应和骨髓抑制共12例次,疗效差异具有统计学意义(P<0.05)。结论:奈达铂化疗联合同期放疗提高中晚期宫颈癌疗效,毒副反应稍有增加但差异无统计学意义(P>0.05)。毒副反应患者能耐受。 Objective: To investigate the clinical efficacy of Nedaplatin combined with concurrent radiotherapy in the treatment of advanced cervical cancer and to summarize the experience of treatment. Methods: Forty patients with advanced cervical cancer were randomly divided into control group and observation group with 20 cases each. The control group received simple radiotherapy and the observation group received nedaplatin-based concurrent chemoradiotherapy. After the end of treatment efficacy and adverse reactions. Results: The total effective rate in the observation group was 90.00%. Adverse reactions were mainly gastrointestinal reactions and bone marrow suppression in 15 cases. The total effective rate was 60.00% in the control group. The main adverse reactions were digestive tract reaction and bone marrow suppression in 12 cases. The difference was statistically significant (P <0.05). Conclusion: Nedaplatin combined with concurrent radiotherapy can improve the curative effect of advanced cervical cancer. The toxic side effects are slightly increased but the difference is not statistically significant (P> 0.05). Toxic patients can tolerate.